Sugi Predict

Sugi Predict / Compounds / Ethylene Glycol Dibutanoate

Ethylene Glycol Dibutanoate

Ethylene Glycol Dibutanoate

SCHEMBL50505

CCCC(=O)OCCOC(=O)CCC.OCCO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.52
▸ ADRA2A P08913 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ MGLL Q99685 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ DNM1 Q05193 1/20 0.42
▸ CYP4F2 P78329 1/20 0.42
▸ CYP4A11 Q02928 1/20 0.42
▸ NAAA Q02083 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ PAM P19021 2/20 0.38
▸ FFAR3 O14843 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol Dibutanoate SCHEMBL104207 0.92 DGKA (0.65) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL50506 0.90 — —
SCHEMBL15636150 0.90 DGKA (0.62) DGKAALDH1A1ADRA2AADRA1AMGLL
Ammonia Solution, Strong SCHEMBL15147557 0.88 MGLL (0.51) DGKAALDH1A1ADRA2AADRA1AMGLL
Propanol SCHEMBL7782732 0.88 ALDH1A1 (0.50) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL28538532 0.88 MGLL (0.51) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL27490783 0.88 MGLL (0.51) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL28861485 0.87 DGKA (0.50) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL11249003 0.87 DGKA (0.50) DGKAALDH1A1ADRA2AADRA1AMGLL
SCHEMBL13220469 0.87 DGKA (0.50) DGKAALDH1A1ADRA2AADRA1AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113527765-A Polylactic acid composition and additive composition thereof, plastic product and preparation method thereof 浙江兴越材料技术有限公司 2021-10-22 — — CN claimed
EP-3076946-B1 COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME ALZET LLC (US) 2026-01-07 — — EP disclosed
US-20250127776-A1 ORAL PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-04-24 — — US disclosed
US-20250057835-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-20 — — US disclosed
US-12097189-B1 Pharmaceutical composition for modified release ASTELLAS PHARMA INC. (JP) 2024-09-24 — — US disclosed
US-20240293307-A1 Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same DURECT CORPORATION (US) 2024-09-05 — — US disclosed
US-11707451-B2 Pharmaceutical composition for modified release ASTELLAS PHARMA INC. (JP) 2023-07-25 — — US disclosed
CN-111918853-B Interlayer film for laminated glass, and method for manufacturing flat panel display system 积水化学工业株式会社 2023-04-18 — — CN disclosed
CN-115612349-A Inkjet ink composition and recording method 精工爱普生株式会社 2023-01-17 — — CN disclosed
CN-113370668-B Ink jet textile printing and recording apparatus and ink jet recording method 精工爱普生株式会社 2023-01-10 — — CN disclosed
US-4256108-A Microporous-semipermeable laminated osmotic system ALZA CORPORATION (US) 1981-03-17 — — US disclosed
US-4203439-A Osmotic system with volume amplifier for increasing amount of agent delivered therefrom ALZA CORPORATION (US) 1980-05-20 — — US disclosed
US-4160452-A Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina ALZA CORPORATION (US) 1979-07-10 — — US disclosed
US-4160020-A CELLULOSE ESTERS, CELLULOSE ETHERS ALZA CORPORATION (US) 1979-07-03 — — US disclosed
US-4111201-A OSMOTIC SYSTEM FOR DELIVERING SELECTED BENEFICIAL AGENTS HAVING VARYING DEGREES OF SOLUBILITY ALZA CORPORATION (US) 1978-09-05 — — US disclosed
US-4111203-A OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM ALZA CORPORATION (US) 1978-09-05 — — US disclosed
US-4111202-A OSMOTIC SYSTEM FOR THE CONTROLLED AND DELIVERY OF AGENT OVER TIME ALZA CORPORATION (US) 1978-09-05 — — US disclosed
US-4077407-A POLYSACCHARIDES ALZA CORPORATION (US) 1978-03-07 — — US disclosed
US-4058122-A Osmotic system with laminated wall formed of different materials ALZA CORPORATION (US) 1977-11-15 — — US disclosed
US-4008719-A Osmotic system having laminar arrangement for programming delivery of active agent ALZA CORPORATION (US) 1977-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11707451-B2 Pharmaceutical composition for modified release SLC6A19, AASDHPPT, SLC6A15 DGKA 4573/4885ALDH1A1 874/4885ADRA2A 105/4885
US-20250127776-A1 ORAL PHARMACEUTICAL COMPOSITION LIPA, CYP2C19, PNLIP DGKA 4079/4885ALDH1A1 2529/4885ADRA2A 215/4885
US-20250057835-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND CYP2C19, CYP2C18, CYP3A7 DGKA 3935/4885ALDH1A1 2303/4885ADRA2A 802/4885
US-12097189-B1 Pharmaceutical composition for modified release SLC6A19, SLC6A15, GART DGKA 4589/4885ALDH1A1 884/4885ADRA2A 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.